Stockreport

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Inc.  (PMN) 
PDF PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month t [Read more]